Appendix 4E and FY26 financial reports
Open PDF
| Stock | Australian Clinical Labs Ltd (ACL.ASX) |
|---|---|
| Release Time | 17 Aug 2026, 8:08 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
ACL FY26 Financial Results
Key Points
- Total revenue down 0.7% to $735.8m
- Underlying profit up 4.6% to $35.2m
- Dividend increased to 9.25 cents per share
Full Summary
Australian Clinical Labs (ACL) reported its FY26 financial results, showing a slight decline in total revenue by 0.7% to $735.8 million. However, underlying profit increased by 4.6% to $35.2 million. Statutory profit decreased by 26.9% to $23.7 million, while underlying earnings per share rose by 8.5% to 18.33 cents. The company declared a final dividend of 9.25 cents per share, fully franked, up from 9.00 cents in the previous year. The company also released its Appendix 4E and FY26 financial reports, providing comprehensive details of its financial performance.
Guidance
FY26 total revenue: $735.8m, underlying profit: $35.2m, earnings per share: 18.33c
Outlook
ACL anticipates continued growth in underlying profit and earnings per share in the coming years.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In